A series of cardiometabolic-related news items has been observed from Insulet, NewAmsterdam Pharma, Protagonist Therapeutics, Biomea Fusion, Vivani Medical, and CVS Health. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: D&D Pharmatech extended its oral obesity research agreement with Pfizer (view article), Dexcom received clearance of its G7 15-Day CGM in Canada (view press release), and Insulet partnered with Calm to provide well-being resources for diabetes management (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Insulet, FDA/Sandoz, Kailera Therapeutics, and Resalis Therapeutics. Below, FENIX provides highlights and insights for the respective news items.
On the third day of the ADA 2026 conference, four cardiometabolic-related news items have been observed from Boehringer Ingelheim, Novo Nordisk, Lilly, and Insulet/EOFlow. Below, FENIX provides context and analysis for the respective news items, including the speculative potential for a 2-day EMDAC featuring survo + reta (spoiler alert: it’s not a 0% chance).
On the second day of the ADA 2026 conference, nine cardiometabolic-related news items have been observed from Pfizer, Abbott, Novo Nordisk, Hengrui/Kailera Therapeutics, Insulet, Dexcom, MannKind, Biomea Fusion, and Tidepool. Below, FENIX provides context and analysis for the announcements.
Three cardiometabolic-related news items have been observed: MiniMed hosted its CY Q1 ‘26 (FY Q4 ’26) earnings call (view press release; view slides); Insulet rolled out an updated O5 algorithm and expanded integration with Libre 3 Plus CGM (view press release); and CamDiab’s myLoop AID + Dexcom G7 CGM integration launched in the EU (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Abbott, Kailera Therapeutics, MiniMed, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.
A series of cardiometabolic-related news items has been observed from FDA, Novo Nordisk, Altimmune, Lilly, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Madrigal Pharmaceuticals hosted its Q1 ’26 earnings call (view press release; view slides) and Insulet hosted its Q1 ’26 earnings call (view press release; view slides). Below, FENIX provides highlights and insights for the respective news items.